LKFT

Galapagos NV ADR

GLPG.US glpg.com
Price N/A
USD · NASDAQ
52-week range
27.15
37.78
Market Cap
1.86B
P/E Ratio
3.18
Forward P/E
303.03
Book Value
2.90
Div. Yield
N/A
% Institutions
22.31%
% Insiders
25.35%

1 Year

+7.5%

3 Year

-34.0%

10 Year

-49.4%
Description

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Company Information

Company Name
Galapagos NV ADR
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US36315X1019
CIK: 0001421876
CUSIP: 36315X101
Currency: USD
Full Time Employees: 704
Phone: 32 1 534 29 00
Website: glpg.com
Fiscal Year End: December
IPO Date: May 06, 2005
Description:

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Address:

Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800

People

Directors & Officers

Name Title Year Born
Mr. Henry Gosebruch CEO & Executive Director NA
Mr. Aaron L. Cox Chief Financial Officer 1984
Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. Head of Investor Relations NA
Mr. Fred W. Blakeslee II Executive VP & General Counsel NA
Marieke Vermeersch Head of Corporate Communication NA
Ms. Tania Philipp Chief Human Resources Officer 1972
Ms. Ellen Van Der Aar Head of Development NA
Ms. Annelies Missotten Executive Officer 1973
Dr. Jeevan Shetty Head of Clinical Development Oncology NA
Ruiz Astigarraga Head of Manufacturing Cell Therapy NA

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
TANG CAPITAL MANAGEMENT LLC 3.79M Mar 31, 2026 5.75% $5.77 -3.45%
Madison Avenue Partners, LP 2.47M Mar 31, 2026 3.74% $3.22 11.39%
EcoR1 Capital, LLC 1.67M Mar 31, 2026 2.53% $2.12 0.00%
Prosight Management, LP 1.55M Mar 31, 2026 2.35% $7.63 44.31%
Ameriprise Financial Inc 1.42M Mar 31, 2026 2.16% $0.01 -1.83%
Segall Bryant & Hamill 426.41K Mar 31, 2026 0.65% $0.18 -4.84%
Point72 Asset Management, L.P. 332.13K Mar 31, 2026 0.50% $0.01 -31.69%
Renaissance Technologies Corp 315.40K Mar 31, 2026 0.48% $0.01 1.55%
BlackRock Inc 312.11K Mar 31, 2026 0.47% $0.00 -0.69%
D. E. Shaw & Co LP 215.72K Mar 31, 2026 0.33% $0.00 -21.56%
UBS Group AG 175.29K Mar 31, 2026 0.27% $0.00 -49.84%
Dafna Capital Management LLC 130.18K Mar 31, 2026 0.20% $0.89 0.00%
Citadel Advisors Llc 124.43K Mar 31, 2026 0.19% $0.00 39.19%
Millennium Management LLC 107.91K Mar 31, 2026 0.16% $0.00 -68.20%
OLD MISSION CAPITAL LLC. 95.59K Mar 31, 2026 0.15% $0.05 0.00%
NORGES BANK 90.00K Dec 31, 2025 0.14% $0.00 -25.00%
Man Group PLC 80.21K Mar 31, 2026 0.12% $0.00 68.57%
Hudson Bay Capital Management LP 77.50K Mar 31, 2026 0.12% $0.01 -54.41%
Tower Research Capital LLC 66.54K Mar 31, 2026 0.10% $0.05 12,041.61%
ALPS Advisors Inc 53.66K Mar 31, 2026 0.08% $0.01 -0.24%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Columbia Overseas Value Inst 746.80K 1.13% ▲ 4.48% Apr 30, 2026
2 Columbia EAFE Value 714.75K 1.08% ▲ 2.50% Mar 31, 2026
3 Columbia EAFE Core 346.55K 0.53% ▼ 10.20% Mar 31, 2026
4 Columbia VP Overseas Core 3 346.55K 0.53% ▲ 0.00% Apr 30, 2026
5 iShares Biotechnology ETF 271.40K 0.41% ▲ 1.95% May 29, 2026
6 Segall Bryant & Hamill Sm Cp Val Ins 94.15K 0.14% ▲ 0.00% Apr 30, 2026
7 Columbia Overseas Core Institutional 3 90.70K 0.14% ▲ 0.00% Apr 30, 2026
8 ALPS Medical Breakthroughs ETF 67.95K 0.10% ▲ 0.00% May 29, 2026
9 Columbia Trust Overseas Value Founders 40.34K 0.06% ▲ 2.18% Apr 30, 2026
10 Barometer International Equity A 39.60K 0.06% ▲ 8.20% May 31, 2026

Financial Highlights

Market Cap: $1.86B
EBITDA: $662.96M
P/E Ratio: $3.18
PEG Ratio: $0.00
Book Value: $2.90
Earnings/Share: $8.71
Profit Margin: 46.83%
Operating Margin: -982.92%
ROA (TTM): 10.66%
ROE (TTM): 16.26%
Revenue (TTM): $1.04B
Revenue/Share (TTM): $0.79
Earnings Growth (YOY): 3,036.00%
Revenue Growth (YOY): -91.40%

Valuation Metrics

Enterprise Value: $-1.59B
Trailing P/E: 3.18
Forward P/E: 303.03

Shares Statistics

Shares Outstanding: 65.90M
Shares Float: 44.52M
% Insiders: 25.35%
% Institutions: 22.31%
Short % Float: 3.39%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$1.11B
Cost of Goods Sold
adjust
$-29.74M
Gross Profit
subtotal
$1.08B
SG&A
adjust
$-110.57M
R&D
adjust
$-459.42M
Other Operating Expense
adjust
$-11.13M
Operating Income
subtotal
$501.39M
Other / Non-Operating Items
adjust
$-180.51M
Net Income
subtotal
$320.88M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about GLPG.US!